Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beximco To Distribute Mylan Product Portfolio In Bangladesh","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"BANGLADESH","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beximco Pharma and Serum Institute of India Announce Intention to Cooperate on A Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"BANGLADESH","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"BANGLADESH","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beximco Pharma Introduces World's First Generic Molnupiravir, an Oral Antiviral Drug For COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"BANGLADESH","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Beximco Pharmaceuticals

    Menu

    Beximco Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Beximco Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Bangladesh
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Beximco Pharma Introduces World's First Generic Molnupiravir, an Oral Antiviral Drug For COVID-19 Treatment

              Details:

              Molnupiravir works by interfering with the replication of virus. This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease.

              Lead Product(s): Molnupiravir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Molnupiravir-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Beximco Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Bangladesh
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide

              Details:

              Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval for the US market.

              Lead Product(s): Flecainide

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Beximco Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Bangladesh
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Beximco Pharma and Serum Institute of India Announce Intention to Cooperate on A Covid-19 Vaccine

              Details:

              Beximco will be the exclusive supplier of the vaccine in Bangladesh and will facilitate the needs of the Government of Bangladesh by offering the opportunity for it to reserve the desired quantities for priority supply at prices to be agreed between the Government and SII.

              Lead Product(s): ChAdOx1 nCoV-19

              Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

              Highest Development Status: Phase III Product Type: Vaccine

              Recipient: Serum Institute of India

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Beximco Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Bangladesh
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Beximco To Distribute Mylan Product Portfolio In Bangladesh

              Details:

              Beximco Pharma will receive the exclusive rights to launch Mylan’s portfolio of key monoclonal antibodies to treat different types of Medical indications.

              Lead Product(s): Trastuzumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Viatris

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY